Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
There is currently no evidence for a dedicated or unique "glicentin receptor." Instead, glicentin acts as an agonist—albeit weakly—at several known class B GPCRs that also bind other proglucagon-derived hormones, primarily the Glucagon Receptor (GCGR), GLP-1 Receptor (GLP-1R), and GLP-2 Receptor (GLP-2R). Its physiological roles are likely mediated through these interactions rather than through a specific exclusive target molecule/receptor.
Agonism at Glucagon Receptor (GCGR), GLP-1 Receptor (GLP-1R), and GLP-2 Receptor (GLP-2R)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glicentin Receptor.